Radiosensitization of TPGS-emulsified docetaxel-loaded poly(lactic-co-glycolic acid) nanoparticles in CNE-1 and A549 cells

Abstract

Docetaxel is among the most effective radiosensitizers. It is widely used as radiosensitizer in many tumors, including head and neck carcinoma. Nevertheless, poor solubility and severe hypersensitivity limit its clinical use and its therapeutic effect remains to be improved. In this study, docetaxel-loaded polymeric nanoparticles were prepared by nanoprecipitation method to be new radiosensitizer with lower side effects and higher efficacy. The physiochemical characteristics of the nanoparticles were studied. Two human tumor cell lines which are resistant to radiotherapy were used in this research. We have compared the radioenhancement efficacy of docetaxel-loaded nanoparticles with docetaxel in A549 and CNE-1 cells. Compared with docetaxel, radiosensitization of docetaxel-loaded nanoparticles was improved significantly (sensitization enhancement ratio in A549 increased 1.24-fold to 1.68-fold when the radiation was applied 2 h after the drug, p < 0.01, sensitization enhancement ratio in CNE-1 increased 1.32-fold to 1.61-fold, p < 0.05). We explored the mechanisms for the radiosensitization efficiency and the difference between docetaxel and docetaxel-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles. The improved radiosensitization efficacy was associated with enhanced G2/M arrest, promoted apoptosis and the role of D-alpha-tocopheryl polyethylene glycol 1000 succinate which will enhance the cell uptake and inhibit the multiple drug resistance. Moreover, the radiosensitization efficacy of docetaxel-loaded nanoparticles was more prominent than docetaxel. In conclusion, tocopheryl polyethylene glycol 1000 succinate-emulsified docetaxel-loaded PLGA nanoparticles were more efficacious and fewer adverse effects were observed than with the commercial docetaxel formulation. Thus, PLGA nanoparticles hold promise as a radiosensitizing agent.

Keywords

Drug-radiation interaction radiosensitivity cancer predisposition cell cycle nanoparticles

Get full access to this article

View all access options for this article.

References

Pajonk

Vlashi

McBride

. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 2010; 28: 639–648.

Kwatra

Venugopal

Anant

. Nanoparticles in radiation therapy: a summary of various approaches to enhance radiosensitization in cancer. Transl Cancer Res 2013; 2: 330–342.

Seiwert

Salama

Vokes

. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 2007; 4: 156–171.

Giuseppe

William

Sophie

. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008; 4: 1089–1094.

Zemskova

Sahakian

Bashkirova

. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem 2008; 283: 20635–20644.

Slevin

. A comparison of cisplatin and fluorouracil alone or with docetaxel in squamous cell carcinoma of the head and neck. Nat Clin Pract Oncol 2008; 5: 306–307.

Sculier

Moro-Sibilot

. First- and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J 2009; 33: 915–930.

Unal

Oguz

Turak

. Ratio of metastatic to examined lymph nodes is a predictor of mortality in locally advanced gastric cancer treated chemo-radiotherapy. Hepatogastroenterology 2014; 61: 2141–2148.

Lee

Nam

. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Res Treat 2008; 109: 481–489.

10.

Toi

Nakamura

Kuroi

. Phase II study of preoperative sequential FEC and docetaxelpredicts of pathological response and disease free survival. Breast Cancer Res Treat 2008; 110: 531–539.

11.

Lisle

Sharon

. Docetaxel with concurrent radiotherapy in head and neck cancer. Semin Oncol 2003; 30: 89–93.

12.

Sen

Saglam

Toker

. Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer. Cancer Chemother Pharmacol 2011; 68: 1497–1505.

13.

Dunne

Mothersill

Robson

. Radiosensitization of colon cancer cell lines by docetaxel: mechanisms of action. Oncol Res 2004; 14: 447–454.

14.

Nabella

Spencer

. Docetaxel with concurrent radiotherapy in head and neck cancer. Semin Oncol 2003; 30: 89–93.

15.

Geng

Zeng

Wang

. Docetaxel shows radiosensitization in human hepatocellular carcinoma cells. World J Gastroenterol 2005; 11: 2990–2993.

16.

Markman

. Managing taxane toxicities. Support Care Cancer 2003; 11: 144–147.

17.

Mei

Zhang

Zheng

. A novel docetaxel-loaded poly (ε-caprolactone)/pluronic f68 nanoparticle overcoming multidrug resistance for breast cancer treatment. Nanoscale Res Lett 2009; 4: 1530–1539.

18.

Gao

Chen

. Targeted nanoassembly loaded with docetaxel improves intracellular drug delivery and efficacy in murine breast cancer model. Mol Pharm 2008; 5: 1044–1054.

19.

Esmaeili

Dinarvand

Ghahremani

. Docetaxel–albumin conjugates: preparation, in vitro evaluation and biodistribution studies. J Pharm Sci 2008; 98: 2718–2730.

20.

Zheng

. Study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma. Acta Biochim Biophys Sin (Shanghai) 2009; 41: 578–587.

21.

Chen

Zheng

Tian

. Oral delivery of DMAB-modified docetaxel loaded PLGA-TPGS nanoparticles for cancer chemotherapy. Nanoscale Res Lett 2011; 6: 4–4.

22.

Chen

. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009; 30: 226–232.

23.

Immordino

Brusa

Arpicco

. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release 2003; 91: 417–429.

24.

Cortes

Pazdur

. Docetaxel. J Clin Oncol 1995; 13: 2643–2655.

25.

Farokhzad

Langer

. Impact of nanotechnology on drug delivery. ACS Nano 2009; 3: 16–20.

26.

Haley

Frenkel

. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008; 26: 57–64.

27.

Cui

Liu

. Enhancement of radiotherapy efficacy by docetaxel-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer. Cancer Lett 2014; 346: 53–62.

28.

Maeda

Sawa

. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271–284.

29.

Werner

Copp

Karve

. Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy. ACS Nano 2011; 5: 8990–8998.

30.

Ranganath

Kee

Krantz

. Hydrogel matrix entrapping PLGA-paclitaxel microspheres: drug delivery with near zero-order release and implantability advantages for malignant brain tumour chemotherapy. Pharm Res 2009; 26: 2101–2114.

31.

Zhang

Tan

Feng

. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 2012; 33: 4889–4906.

32.

Gan

Feng

. Transferrin-conjugated nanoparticles of poly (lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 2010; 31: 7748–7757.

33.

Zhang

Feng

. Copolymer technology for nanomedicine. Nanomedicine 2011; 6: 583–587.

34.

Win

Feng

. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005; 26: 2713–2722.

35.

Zhang

Lee

Gan

. In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm Res 2008; 25: 1925–1935.

36.

Zhang

Feng

. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006; 27: 262–270.

37.

Zhang

Tan

Feng

. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 2012; 33: 4889–4906.

38.

Win

Feng

. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolid acid) nanoparticles for paclitaxel formulation. Biomaterials 2006; 27: 2285–2291.

39.

Barichello

Morishita

Takayama

. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 1999; 25: 471–476.

40.

Shi

Zhang

Yuan

. Optimization of parameters for preparation of docetaxel-loaded PLGA nanoparticles by nanoprecipitation method. J Huazhong Univ Sci Technol 2013; 33: 754–758.

41.

Zhang

Feng

. Nanoparticles of poly (lactide)/Vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006; 27: 262–270.

42.

Win

Feng

. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005; 26: 2713–2722.

43.

Qaddoumi

Ueda

Yang

. Uptake of biodegradable nanoparticles in pigmented rabbit conjunctival epithelial cells. Invest Ophthalmol Visual Sci 2000; 41: S765–S765–S765–S765.

44.

Caffo

. Radiosensitization with chemotherapeutic agents. Lung Cancer 2001; 34: S81–S90.

45.

Jain

Paczulla

Klonisch

. Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development. J Cell Mol Med 2013; 17: 12–29.

46.

Wiem

Sırma

Mohamed

E-G

. Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer. Arch Immunol Ther Exp 2013; 61: 43–58.

47.

Los

Gibson

. Apoptotic pathways as target for novel therapies of cancer and other diseases, New York: Springer, 2005.

48.

Lin

Liu

Chau

. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 2000; 89: 983–994.

49.

Brannon-Peppas

Blanchette

. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004; 56: 1649–1659.

50.

Davis

Chen

Shin

. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008; 7: 771–782.

51.

Creane

Seymour

Colucci

. Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizer. Int J Radiat Biol 1999; 75: 731–737. .

52.

Varadarajan

Sellakumar

Gerhold

. Modulation of docetaxel-induced apoptosis and cell cycle arrest by all-trans retinoic acid in prostate cancer cells. Br J Cancer 2001; 84: 1571–1576.

53.

Abal

Andreu

Barasoain

. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003; 3: 193–203.

54.

Dintaman

Silverman

. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999; 16: 1550–1556.

55.

Zhang

Tan

Feng

. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 2012; 33: 4889–4906.